Massimo Radin

TL;DR: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option and an improvement in respiratory and laboratory parameters was observed, requiring future controlled trials to confirm the definite benefit with IL-6 target therapy.

TL;DR: Based on analysis of the international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.

TL;DR: In this paper, the authors conducted a literature search to identify articles reporting clinical experience with the use of eculizumab in SLE patients, focusing on renal involvement, and reported promising results.

TL;DR: An overall estimated median prevalence of anti‐&bgr;2 GPI‐DI antibodies of 44.3% is reported in patients with APS and/or SLE and a significantly higher prevalence among patients withAPS compared with SLE alone, which might represent a promising tool when assessing thrombotic risk in patientsWith APS.

TL;DR: Available data are promising and provide preliminary support for targeting BlyS to induce or maintain a renal response in lupus nephritis and further trials should examine whether belimumab (alone or following rituximab) represents an additional therapeutic option in the treatment of LN.